SCHEMBL5559845

SCHEMBL5559845

CCCC(=O)NS(=O)(=O)c1ccc(C(=O)C=Cc2cc(N3CCCC3)c(OC)cc2OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
PTPN1 P18031 9/20 0.47
ABCG2 Q9UNQ0 1/20 0.46
MAOB P27338 1/20 0.41
DPP4 P27487 4/20 0.40
ALDH1A1 P00352 2/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTGS2 P35354 1/20 0.39
KDM4E B2RXH2 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5559840 1.00 LMNA (0.49) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5565945 0.84 LMNA (0.51) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5565954 0.84 LMNA (0.51) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5564581 0.82 PTPN1 (0.58) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5564576 0.82 PTPN1 (0.58) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5559837 0.80 ALDH1A1 (0.39) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5560194 0.79 MEN1 (0.52) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5560192 0.79 MEN1 (0.52) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5559747 0.79 HTR7 (0.49) LMNAMAPTSMN1; SMN2MEN1GAA
SCHEMBL5559740 0.79 HTR7 (0.49) LMNAMAPTSMN1; SMN2MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 LMNA 2762/4885MAPT 2572/4885SMN1; SMN2 1575/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 LMNA 2762/4885MAPT 2572/4885SMN1; SMN2 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.